Simplification to Efavirenz-Tenofovir DF-Emtricitabine

ADONE Trial
Simplification to Efavirenz-Tenofovir DF-Emtricitabine
ADONE: Study Design

Study Design: ADONE Study

- **Background**: Prospective, comparative, open-label study evaluating the advantages of switching to one-pill-once a day with efavirenz-tenofovir DF-emtricitabine

- **Inclusion Criteria** (n = 212)
  - Stable on ART with EFV + TDF + FTC (or 3TC)
  - HIV RNA <50 copies/mL

- **Treatment (Switch) Arm**
  - Efavirenz-Tenofovir DF-Emtricitabine

Simplification to Efavirenz-Tenofovir DF-Emtricitabine
ADONE: Result

Week 48 Virologic Response (ITT Analysis, M=F)

Simplification to Efavirenz-Tenofovir DF-Emtricitabine
ADONE: Result

Week 48 CD4 Cell Count Response

Mean CD4 count (cells/mm$^3$)

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>556</td>
<td>605</td>
</tr>
</tbody>
</table>

Simplification to Efavirenz-Tenofovir DF-Emtricitabine
ADONE: Result

Improvement in Adherence Following Switch to One-Pill-Once-A-Day

![Bar chart showing change in adherence (%).]

Interpretation: “By substituting a one-pill once-a-day HAART, we observed an improvement of both adherence and QoL while maintaining high virologic and immunologic efficacy. HAART simplicity is an added value that favors adherence and may improve long-term success.”
The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

*The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.*